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Abstract
Background—Immigrants and refugees 2–14 years of age entering the United States from 
countries with estimated tuberculosis (TB) incidence rate ≥20 per 100,000 population are screened 
for TB. Children with TB disease are treated before US arrival. Children with positive tuberculin 
skin tests (TST), but otherwise negative TB evaluation during their pre-immigration medical 
examination, are classified with latent TB infection (LTBI) and are recommended for re-evaluation 
post-arrival. We examined post-immigration TB evaluation and therapy for children arriving with 
LTBI.
Methods—We reviewed medical exam data from immigrant children with medical conditions 
and all refugee children arriving during 2010.
Results—Medical examination data were available for 67,334 children. Of these, 8,231 (12%) 
had LTBI pre-immigration; 5,749 (70%) were re-evaluated for TB post-immigration, and 64% 
were retested by TST or IGRA. The pre-immigration LTBI diagnosis was changed for 38% when 
retested by TST and for 71% retested by IGRA. Estimated LTBI therapy initiation and completion 
rates were 68% and 12%.
Conclusions—In this population, testing with IGRA may limit the number of children targeted 
for therapy. Increased pre-immigration TB screening with post-immigration follow-up evaluation 
leading to completion of LTBI therapy should be encouraged to prevent TB reactivation.
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Background
Despite a 6.4% decrease in the rate of new tuberculosis (TB) cases in the U.S. from 2010 to 
2011, foreign-born person living in the United States continue to be disproportionately 
affected by TB (1). In 2011, a total of 6,546 TB cases were reported among foreign-born 
persons, and the rate of incident TB cases among foreign-born persons in the United States 
was 12 times greater than among U.S.-born persons (1). Thus, one crucial component of TB 
elimination in the United States is addressing differences between TB rates in foreign- and 
U.S.-born persons (1).
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In 2011, approximately 80% of foreign-born persons were diagnosed with TB after being in 
the United States for more than 2 years, consistent with reactivation of latent tuberculosis 
infection (LTBI) acquired abroad (1). Because LTBI treatment reduces the potential for 
progressing to active disease, LTBI screening and treatment, particularly among foreign-
born persons, has become a critical part of the strategy for eliminating TB disease in the 
United States (2–6).
In 2007, the Centers for Disease Control and Prevention’s (CDC) Division of Global 
Migration and Quarantine (DGMQ) published updated requirements for pre-immigration TB 
screening in prospective migrants to the United States (also known as the culture and 
directly observed therapy [CDOT] TB Technical Instructions) which included screening with 
tuberculin skin test (TST) or interferon gamma release assay (IGRA) for children 2–14 years 
of age living in countries with an estimated tuberculosis incidence rate of ≥20 cases per 
100,000 (7). By the end of 2010, 30 countries had implemented these Technical Instructions. 
This TB screening provides a unique opportunity to diagnose children with LTBI prior to 
their arrival and increase the number of infected children who can receive preventive TB 
treatment upon arrival in the United States (7, 8). We analyzed data from CDC’s Electronic 
Disease Notification System (EDN) to assess post-immigration evaluations and TB therapy 
for children who entered the United States after being diagnosed with LTBI during the pre-
immigration medical examination.
Study Population and Methods
We obtained data on age, country of origin, pre-immigration screening results, and post-
immigration tuberculosis follow-up from EDN, a web-based system that provides state and 
local health departments with access to the pre-immigration medical exam results. The pre-
immigration medical exam is required for all immigrants and refugees immigrating to the 
United States, but a post-immigration health assessment is only recommended and is 
suggested to occur within 90 days of arrival. EDN notifications are available for all refugee 
arrivals but for only those immigrants with a medical condition of public health significance, 
such as LTBI. Health departments report TB evaluation and treatment outcomes to CDC 
through the TB follow-up module of EDN.
To determine the age and country-specific frequencies of arrivals, the numbers were 
extracted from EDN for refugees and from the Department of Homeland Security (DHS) for 
immigrants. EDN only includes immigrants with medical conditions, so DHS data were 
required to obtain the denominators for immigrants(9).
LTBI was defined as having a positive TST result (≥10 mm induration) or a positive IGRA 
result, normal chest radiograph, and otherwise negative TB evaluation. Post-immigration 
follow-up was considered reported if a TB follow-up worksheet had been initiated in the 
EDN system. We reviewed pre-immigration medical exam information and post-
immigration TB follow-up data for immigrant and refugee children 2–14 years of age who 
arrived in the United States during the 2010 calendar year from countries that had 
implemented the 2007 technical instructions (10).
Taylor et al. Page 2
J Immigr Minor Health. Author manuscript; available in PMC 2018 July 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We calculated the prevalence of LTBI diagnosed during the pre-immigration exam among 
immigrant and refugee children arrivals in 2010. TB screening results from the post-
immigration visit were evaluated for persons with LTBI. LTBI prevalence and demographic 
characteristics among immigrants and refugees were compared for statistically significant 
differences by the chi-square test. Analyses were done in SAS Enterprise Guide, version 5.1. 
Reported P values are two-sided and were not adjusted for multiple testing.
This analysis was determined during human subjects review to be part of CDC’s public 
health surveillance activities and therefore approval by an institutional review board was not 
required.
Results
During the 2010 calendar year, 67,334 children 2–14 years of age who were screened under 
the 2007 tuberculosis Technical Instructions arrived in the United States: 53,939 (80%) were 
immigrants, and 13,395 (20%) were refugees. Only 15 (0.26%) cases were Mycobacterium 
tuberculosis culture-positive and had completed tuberculosis treatment prior to arrival in the 
United States. A total of 8,231 (12%) of the 67,334 children included in this analysis were 
diagnosed with LTBI during the pre-immigration exam (Figure 1). Overall, LTBI prevalence 
rates were higher among immigrants (7,400/53,939=14%) than refugees (831/13,395=6%) 
(p=0.002).
Demographic characteristics of children diagnosed with LTBI during their pre-immigration 
exam are presented by visa type in table 1. More than half (55%) of these children were 10–
14 years of age, and there was an equal proportion of males and females. Refugees were 
significantly more likely than immigrants to have been born in a country with a TB 
incidence ≥100 cases per 100,000 (86% vs. 64%; p<0.0001,).
About 70% of children who arrived in the United States with a diagnosis of LTBI had a post-
immigration follow-up exam reported to CDC, and post-immigration follow-up reporting 
was similar for immigrants and refugees. Of the 5,749 children who arrived with a diagnosis 
of LTBI and had post-immigration follow-up, 3,299 (57%) were diagnosed with LTBI in the 
United States at the post-immigration exam.
The type of TB test conducted in the United States and the post-immigration LTBI diagnosis 
is shown in Table 2. Of those with LTBI with a post-immigration LTBI evaluation reported 
visit, 35% received only a TST, 23% received only an IGRA, 6% received both a TST and 
IGRA, and 36% had no post-immigration TB test documented. The majority of those 
retested with TST (62%) had their pre-immigration diagnosis of LTBI confirmed in the 
United States, while 71% of those retested with an IGRA had their pre-immigration 
diagnosis of LTBI reversed (Table 2). Seventy-two percent of children who received both 
tests in the United States had discordant results (a positive TST result and negative IGRA 
result).
Estimated that LTBI therapy initiation and completion rates were 68% and 12%, respectively 
(Figure 1). LTBI therapy initiation was slightly greater among refugees than immigrants, but 
therapy completion was the same for both groups (data not shown). Of note, 12% of children 
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had missing data for LTBI therapy initiation, and 59% had missing data for LTBI therapy 
completion. On the basis of calculations assuming complete compliance and complete 
refusal for those with missing data, the true LTBI therapy initiation rate could be 61%–72% 
and the true LTBI therapy completion rate could be 19%–56%.
Discussion
It is estimated that 4% of the total US population has LTBI (11), although the rate among 
newly arriving immigrant and refugee children has been less well described. We found that 
12% of children arriving in the United States during 2010 were diagnosed with LTBI during 
the pre-immigration medical examination. Foreign-born persons in the United States 
continue to experience disproportionately higher TB infection rates than persons born in the 
United States. Pre-immigration LTBI screening combined with follow-up evaluation in the 
United States presents a unique opportunity to prevent tuberculosis among children arriving 
from high-TB incidence countries.
Through follow-up with US health providers, 2,258 immigrant and refugee children who 
arrived in the United States with LTBI in 2010 initiated LTBI therapy and more than 600 
children had documented completion. Completing therapy for LTBI benefits the infected 
individual and society as a whole by preventing active, infectious tuberculosis cases from 
developing (12).
We found the proportion of missing data in EDN increased at each step of the post-
immigration TB follow-up continuum, thus our LTBI therapy initiation and completion rates 
of 68% and 12%, respectively, are subject to bias. Approximately 12% of children with 
LTBI in our analysis had missing data for treatment initiation and 59% had missing data for 
treatment completion. Published estimates of LTBI therapy completion rates among foreign-
born and recent immigrant children in the United States vary from 38% to 82% (13–16), 
which overlaps with the rates of our sensitivity analysis (19%–56%).
A majority (62%) of the children included in our analysis were re-tested for TB during their 
post-immigration exam, most commonly by using a TST. In its guidance on testing newly 
arrived refugees for TB, CDC advises against repeating a TST if a documented previous 
positive TST result is available (17). In 1996, CDC recommended disregarding prior 
Bacillus Calmette–Guérin (BCG) immunization when interpreting a positive TST(18). But 
following the approval by the US Food and Drug Administration of two IGRAs, the 
recommendation was revised in 2010 to state that IGRAs were the preferred initial test for 
persons who are likely to have received BCG vaccine (4). CDC guidance for retesting a 
BCG-vaccinated patient who has a positive TST with an IGRA is worded cautiously, stating 
that it may be considered in BCG vaccinated populations where a positive IGRA may 
encourage compliance with therapy or when a patient has otherwise low risk for progression 
[4]. In this analysis, most of the TST-positive children retested by using IGRA had a 
negative IGRA result, possibly due to prior BCG vaccination or other non-tuberculous 
mycobacteria (19, 20). Through decreased false positive tests, we estimate that IGRA could 
reduce by 71% the proportion of children who require LTBI therapy, which may be another 
important consideration when considering retesting BCG vaccinated populations.
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IGRAs are not the preferred testing method for use in children younger than 5 years old (4, 
17). On the basis of the recommendations, we would have expected to see a difference in the 
type of TB test conducted during the post-immigration exam by age. However, 15% of 
children who received an IGRA during their post-immigration exam were in the 2 to 4 year 
age group, and the type of test administered during the post-immigration exam did not differ 
by age.
Our analysis has limitations. First, our results may not be generalizable to all children 
entering the United States because we only included children who received their pre-
immigration medical examination from the 30 countries following the revised 2007 TB TIs 
as of January 1, 2010; nonimmigrant visitors were also not included. Second, results may be 
biased by missing data. Because there is no standardized schedule for when to report TB 
follow-up data to EDN, some states report data when the initial evaluation is completed, 
while others do not report any information to EDN until follow-up is complete. The low 
numbers for treatment initiation and completion we observed could either be a true lack of 
LTBI treatment initiation and completion or a lack of documentation (i.e. missing data). 
Although CDC DGMQ issues guidelines for US health care providers examining newly 
arriving refugees (17), post-immigration exams are not required and the content and 
reporting of these exams varies by state.
CDC is currently working with state and local healthcare providers to improve forms for 
collecting post-immigration TB follow-up information and develop specific instructions for 
how and when to report data to EDN. Finally, reasons for not initiating or completing LTBI 
therapy are not currently captured in EDN, thus we were unable to examine them in this 
analysis.
By virtue of their young age, children with LTBI have the largest lifetime (i.e., cumulative) 
risk for activation of latent tuberculosis (assuming no other risk factors), and are therefore an 
important group to target for preventive therapy. Currently, many immigrant and refugee 
children with LTBI are not completing preventive therapy. In this population, probably 
vaccinated with BCG, testing with an IGRA may limit the number of children targeted for 
preventive therapy.
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Figure 1. 
Post-immigration TB follow-up continuum for immigrants and refugees age 2–14 years 
diagnosed with LTBI pre-immigration in countries implementing the 2007 TB TIs in 
calendar year 2010.
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Table 1.
Characteristics of immigrants and refugees age 2–14 years diagnosed with LTBI pre-immigration by visa type 
(N=8,231)
Immigrant
N=7,400
Refugee
N=831
N (%) N (%)
Age (years)
2–4 847 (11) 77 (9)
5–9 2464 (33) 237 (29)
10–14 4089 (55) 517 (62)
Sex
Male 3741 (51) 441 (53)
Female 3659 (49) 390 (47)
TB Incidence in Birth Country (cases per 100,000)*
20–99 2662 (36) 117 (14)
≥100 4729 (64) 714 (86)
Post-immigration Follow-up Reported
No 2207 (30) 275 (33)
Yes 5193 (70) 556 (67)
*
Effective sample size = 8,222; 9 children missing birth country data
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Table 2.
Post-immigration LTBI evaluation and LTBI diagnosis by type of TB test conducted among arrivals with a 
pre-immigration LTBI diagnosis (N=5,159)*
Post-immigration
LTBI Evaluation
Final
LTBI Diagnosis
Type of Post-immigration Test N (% Total) N (% Diagnosed)
TST Only 1807 (35) 1108 (62)
IGRA Only 1168 (23) 339 (29)
TST and IGRA 317 (6) 79 (25)
No Post-immigration Test Conducted 1867 (36) 1677 (90)
*
Effective sample size = 5,159 with a pre-immigration LTBI diagnosis and post-immigration follow-up reported in EDN; 5,749 had post-
immigration follow-up reported in EDN; 590 missing diagnosis and/or post-immigration testing information
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